	US 12,304,939 B2
	EGFR and C-met fibronectin type III domain binding molecules
Mark Anderson, Norristown, PA (US); Ricardo Attar, Lawrence Township, NJ (US); Michael Diem, Havertown, PA (US); Linus Hyun, King of Prussia, PA (US); Steven Jacobs, North Wales, PA (US); Alastair King, Lake Saint Louis, MO (US); Donna Klein, Philadelphia, PA (US); Sheri Moores, Wayne, PA (US); Karyn O'Neil, Media, PA (US); and Kristen Picha, Malvern, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Feb. 12, 2021, as Appl. No. 17/174,524.
Application 17/174,524 is a division of application No. 15/637,276, filed on Jun. 29, 2017, granted, now 10,954,284.
Application 15/637,276 is a division of application No. 14/086,250, filed on Nov. 21, 2013, granted, now 9,725,497, issued on Aug. 8, 2017.
Claims priority of provisional application 61/809,541, filed on Apr. 8, 2013.
Claims priority of provisional application 61/782,550, filed on Mar. 14, 2013.
Claims priority of provisional application 61/728,914, filed on Nov. 21, 2012.
Claims priority of provisional application 61/728,912, filed on Nov. 21, 2012.
Claims priority of provisional application 61/728,906, filed on Nov. 21, 2012.
Prior Publication US 2021/0206825 A1, Jul. 8, 2021
Int. Cl. A61K 38/16 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/78 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 14/705 (2013.01) [C07K 14/47 (2013.01); C07K 14/71 (2013.01); C07K 14/78 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); C07K 2317/31 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2318/20 (2013.01); C07K 2319/70 (2013.01)]

8 Claims

1. A method of treating a subject having cancer associated with elevated epidermal growth factor receptor (EGFR) activity and/or expression levels, comprising administering a therapeutically effective amount of the pharmaceutical composition comprising a protein comprising a peptide having the amino acid sequence of SEQ ID NO:108 and a pharmaceutically acceptable carrier to the subject.